BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
See today's BioWorld
Home
» FDA queries Arrowhead on phase II tox in HBV; ARC-520 put on hold
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA queries Arrowhead on phase II tox in HBV; ARC-520 put on hold
Nov. 10, 2016
By
Randy Osborne
No Comments
Arrowhead Pharmaceuticals Inc. “should receive a letter from the [FDA] within 30 days that spells out what they want,” President and CEO Christopher Anzalone told BioWorld Today.
BioWorld